Chemistry:Omidenepag isopropyl
 | |
| Clinical data | |
|---|---|
| Trade names | Eybelis |
| Other names | DE-117 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C26H28N6O4S |
| Molar mass | 520.61 g·mol−1 |
Omidenepag isopropyl (INN; trade name Eybelis) is a pharmaceutical drug used for the treatment of glaucoma and ocular hypertension.
Medical uses
Omidenepag isopropyl as a 0.002% ophthalmic solution was approved in Japan in 2018 for the treatment of glaucoma and ocular hypertension.[1] It is being evaluated in the United States and Singapore for the same indications.[1]
Adverse effects
The most common adverse effects of omidenepag isopropyl are conjunctival hyperemia and macular edema, including cystoid macular edema.[1]
Pharmacology
Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.[2] Omidenepag is a selective prostaglandin E2 receptor agonist.[3][4]
History
Omidenepag isopropyl was developed by Ube Industries and Santen Pharmaceutical.[1]
References
- ↑ 1.0 1.1 1.2 1.3 "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs 78 (18): 1925–1929. December 2018. doi:10.1007/s40265-018-1016-1. PMID 30465134.
- ↑ "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. https://drugcentral.org/drugcard/5312.
- ↑ "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science 59 (1): 145–153. January 2018. doi:10.1167/iovs.17-22745. PMID 29332128.
- ↑ "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports 10 (1): 16018. September 2020. doi:10.1038/s41598-020-72538-x. PMID 32994409. Bibcode: 2020NatSR..1016018I.
 |
